The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Management of Endocrine Disease: Osteogenesis imperfecta: an update on clinical features and therapies
Open accessAbstract
Osteogenesis imperfecta (OI) is an inherited skeletal dysplasia characterized by bone fragility and skeletal deformities. While the majority of cases are associated with pathogenic variants in COL1A1 and COL1A2, the genes encoding type I collagen, up to 25% of cases are associated with other genes that function within the collagen biosynthesis pathway or are involved in osteoblast differentiation and bone mineralization. Clinically, OI is heterogeneous in features and variable in severity. In addition to the skeletal findings, it can affect multiple systems including dental and craniofacial abnormalities, muscle weakness, hearing loss, respiratory and cardiovascular complications. A multi-disciplinary approach to care is recommended to address not only the fractures, reduced mobility, growth and bone pain but also other extra-skeletal manifestations. While bisphosphonates remain the mainstay of treatment in OI, new strategies are being explored, such as sclerostin inhibitory antibodies and TGF beta inhibition, to address not only the low bone mineral density but also the inherent bone fragility. Studies in animal models have expanded the understanding of pathomechanisms of OI and, along with ongoing clinical trials, will allow to develop better therapeutic approaches for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Horwitz, E. M., Gordon, P. L., Koo, W. K. K., Marx, J. C., Neel, M. D., McNall, R. Y., Muul, L., & Hofmann, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132252399 · Cited by 1,650
Marini, J. C., Forlino, A., Bächinger, H. P., Bishop, N. J., Byers, P. H., Paepe, A. D., Fassier, F., Fratzl-Zelman, N., Kozloff, K. M., Krakow, D., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.52 · Cited by 842
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Nosology and classification of genetic skeletal disorders: 2019 revision
Mortier, G. R., Cohn, D. H., Cormier‐Daire, V., Hall, C., Krakow, D., Mundlos, S., Nishimura, G., Robertson, S., Sangiorgi, L., Savarirayan, R., et al. (2019) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61366 · Cited by 600
Le Blanc, K., Götherström, C., Ringdén, O., Hassan, M., McMahon, R., Horwitz, E., Anneren, G., Axelsson, O., Nunn, J., Ewald, U., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000159029.48678.93 · Cited by 459
Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype.
Erlebacher, A., & Derynck, R. (1996) · The Journal of cell biology · doi:10.1083/jcb.132.1.195 · Cited by 371
Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta
Grafe, I., Yang, T., Alexander, S., Homan, E. P., Lietman, C., Jiang, M. M., Bertin, T., Munivez, E., Chen, Y., Dawson, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3544 · Cited by 306
Munns, C. F., Rauch, F., Zeitlin, L., Fassier, F., & Glorieux, F. H. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040814 · Cited by 276
Semler, O., Garbes, L., Keupp, K., Swan, D., Zimmermann, K., Becker, J., Iden, S., Wirth, B., Eysel, P., Koerber, F., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.06.011 · Cited by 241
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta
Orwoll, E. S., Shapiro, J., Veith, S., Wang, Y., Lapidus, J., Vanek, C., Reeder, J. L., Keaveny, T. M., Lee, D. C., Mullins, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71101 · Cited by 210
Cited by
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
Xiaohui, T., Wang, L., Yang, X., Jiang, H., Zhang, N., Zhang, H., Li, D., Li, X., Zhang, Y., Wang, S., et al. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.05.004 · Cited by 10
“Rare bone diseases, including osteogenesis imperfecta (OI) and X-linked hypophosphatemia (XLH), affect the musculoskeletal system and may cause severe mobility problems due to painful fractures, de-formities, and bone pain [5,6].”
Background
Metadata
- Authors
- Marom, R., Rabenhorst, B. M., & Morello, R.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-10
- Volume
- 183
- Issue
- 4
- Pages
- R95-R106
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W3039181784
- Cited by
- 263
- References
- 59
- FWCI
- 14.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Endocrine Disease: Osteogenesis imperfecta: an update on clinical features and therapies. https://app.cochat.ai/papers/10.1530/eje-20-0299
- The paper
- Marom, R., Rabenhorst, B. M., & Morello, R. (2020). Management of Endocrine Disease: Osteogenesis imperfecta: an update on clinical features and therapies. European Journal of Endocrinology. https://doi.org/10.1530/eje-20-0299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.